Iron metabolism and lymphocyte characterisation during Covid-19 infection in ICU patients: an observational cohort study.

Giuliano Bolondi (med.bolondi@gmail.com)  
Ospedale Maurizio Bufalini  
https://orcid.org/0000-0002-5627-8445

Emanuele Russo  
Ospedale Maurizio Bufalini

Emilliano Gamberini  
Ospedale Maurizio Bufalini

Alessandro Circelli  
Ospedale Maurizio Bufalini

Manlio Cosimo Claudio Meca  
Ospedale Maurizio Bufalini

Etrusca Brogi  
Ospedale Maurizio Bufalini

Lorenzo Viola  
Ospedale Maurizio Bufalini

Luca Bissoni  
Ospedale Maurizio Bufalini

Venerino Poletti  
Aarhus Universitetshospital

Vanni Agnoletti  
Ospedale Maurizio Bufalini

Research article

Keywords: Iron, COVID-19, SARS-CoV-2, Coronavirus, Critical Care, Lymphocytes, Lymphopenia, Ferritins, Immunity, Coagulation

Posted Date: June 14th, 2020

DOI: https://doi.org/10.21203/rs.3.rs-26288/v2

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License

Version of Record: A version of this preprint was published on June 30th, 2020. See the published version at https://doi.org/10.1186/s13017-020-00323-2.
Abstract

Background: Iron metabolism and immune response to SARS-CoV-2 have not been described yet in intensive care patients, although they are likely involved in Covid-19 pathogenesis.

Methods: We performed an observational study during the peak of pandemic in our intensive care unit, dosing D-dimer, C-reactive protein, Troponin T, Lactate Dehydrogenase, Ferritin, Serum iron, Transferrin, Transferrin Saturation, Transferrin Soluble Receptor, Lymphocyte count and NK, CD3, CD4, CD8, B subgroups of 31 patients during the first two weeks of their ICU stay. Correlation with mortality and severity at the time of admission was tested with Spearman coefficient and Mann-Whitney test. Trends over time were tested with Kruskall-Wallis analysis.

Results: Lymphopenia is severe and constant, with a nadir on day 2 of ICU stay (median 0.555 \(10^9\)/L; interquartile range (IQR) 0.450 \(10^9\)/L); all lymphocytic subgroups are dramatically reduced in critically ill patients, while CD4/CD8 ratio remains normal. Neither Ferritin nor lymphocyte count follow significant trends in ICU patients. Transferrin Saturation is extremely reduced at ICU admission (median 9%; IQR 7%), then significantly increases at day 3 to 6 (median 33%, IQR 26.5%, p-value 0.026). The same trend is observed with serum iron levels (median 25.5 µg/L, IQR 69 µg/L at admission; median 73 µg/L, IQR 56 µg/L on day 3 to 6) without reaching statistical significance. Hyperferritinemia is constant during intensive care stay: however, its dosage might be helpful in individuating patients developing hemophagocytic lymphohistiocytosis. D-dimer is elevated and progressively increases from admission (median 1319 µg/L; IQR 1285 µg/L) to day 3 to 6 (median 6820 µg/L; IQR 6619 µg/L), despite not reaching significant results. We describe trends of all the above mentioned parameters during ICU stay.

Conclusions: The description of iron metabolism and lymphocyte count in Covid-19 patients admitted to the Intensive Care Unit provided with this paper might allow a wider understanding of SARS-CoV-2 pathophysiology.

Background

Covid-19 has been declared a pandemic by World Health Organization (WHO) on the 11th of March. The high contagiousness and the previously unknown clinical features of this new viral infection put under pressure healthcare systems and clinicians worldwide.

Early reports from the Chinese province of Hubei described some predictive biomarkers for the clinical outcome of hospitalised patients, namely lymphopenia and the elevation of D-dimer, ferritin, interleukin 6 (IL-6), troponin and myoglobin, C-reactive protein (CRP) and lactate dehydrogenase (LDH) [1,2]. LDH is a marker of parenchymal lung damage, troponin and myoglobin are markers of myocardial and muscular involvement, while the remaining molecules belong to the group of positive acute-phase proteins (APP).

Ferritin is a crucial component of iron metabolism, one of the most ancestral systems of host protection from pathogen infections [3]. Iron is a micronutrient necessary for both energy production at a mitochondrial level and nucleic acid replication at cytoplasmic and nuclear level. For its scarcity in the human body and the fundamental processes in which it is involved, pathogens (bacterial, viral or fungal) compete with the host for iron availability in order to guarantee their own replication. When innate immunity is activated and cytokine cascades start, IL-1 and IL-6 stimulate hepcidin expression in the liver, reducing iron bioavailability by decreasing its gut absorption and hiding it into ferritin, a shell-like molecule deposited in macrophages. These mechanisms have been extensively reviewed in the literature [4–8].

Lymphopenia and specific T-cell lineage affection are characteristic features of Covid-19 and have been correlated with poorer prognosis [9–11]. In previous Coronavirus outbreaks, such as SARS, the peak of viral load occurred 7 days after symptoms development, followed by elevation in IL-6 and IL-8, nadir lymphocyte count and successive pulmonary infiltrates. This description suggests that clinical symptoms might be mediated by the immune system deregulation rather than direct viral damage [12]. The distribution of different subtypes of T-cells in peripheral blood of symptomatic critical and non-critical Covid-19 patients has been described [13–16].

With this observational study, we aim to provide a detailed description of iron metabolism and lymphocyte subpopulations in ICU Covid-19 population. It can lead to a better understanding of the underlying physiopathology of this unknown disease, foreseeing some possible alternative therapeutic targets.

Methods

Study population:

This is a single-centre retrospective observational cohort study. The first COVID-19 positive patient in our ICU has been admitted on the 5th of March 2020. Data collection goes from the 6th of March to the 6th of April 2020, following the local peak of epidemic. A protocol was established to test predictive biomarkers [shortened]. On the day of ICU admission and then twice-a-week (on Monday and Thursday) every ICU patient was tested for: ferritin, serum iron, transferrin and transferrin saturation (TfSat), soluble receptor of transferrin, CRP D-dimer, LDH, troponin, lymphocyte count, characterisation of T cells (CD3, CD4 and CD8), B cells and NK cells. Then, data were divided in the following sub-categories: TI1-2 (first dosage made on ICU admission), TI3-6 (dosage...
between day 3 to 6 of ICU stay), Ti 7-10 and Ti 11-14. We observed their trends during the first 2 weeks of ICU stay. Due to laboratory restrictions, just 9 patients were tested for Interleukin-6 (IL6) only on the day of admission [17].

Inclusion criteria: every SARS-CoV-2 positive patient (oropharyngeal swab or bronchoalveolar lavage sample, PCR test) admitted to our ICU was automatically enrolled in the study. Overall, 31 patients entered in the final data analysis fulfilling inclusion criteria. Importantly, we count ICU length-of-stay (LOS) from the day of admission in the first ICU; this means that dosages of patients transferred to our unit from other ICUs do not start from day 1.

Data collection ended with the following criteria: data collection was stopped after day 18 of ICU stay; iron-related data analysis was stopped or not taken into account for the final analysis if bacterial infection occurred, since we considered it a known confounding factor for inflammatory response; patients were discharged from our analysis on the date of extracorporeal membrane oxygenation (ECMO) start (3 patients) or death.

Exclusion criteria: all patients, admitted for strict clinical monitoring, discharged within 48 hours from ICU; all admitted patients who tested negative for SARS-CoV-2; no underaged patients were included. Overall, 6 patients were initially tested but then excluded from the final analysis for the above-mentioned criteria.

Outcomes: the primary outcome was a descriptive analysis of iron metabolism values and lymphocyte count in ICU patients. Then, as a secondary outcome, we tried to correlate iron metabolism parameters and lymphocyte count with mortality or severity at the moment of ICU admission. Severity at the moment of ICU admission was quantified with two parameters: mean PaO₂/FiO₂ ratio [18] during the first 24 hours (PFmed) and Platelet-to-Lymphocyte ratio [19] (PLR) on the day of ICU admission (data reported on Table 1).

Measurement technology: iron parameters were tested with Cobas analyser systems (Roche®), while lymphocyte subpopulations with the Navios EX flow cytometer (Beckman Coulter®).

Statistical analysis:

The formula used to estimate TfSat (TfSat = Serum Iron/(Transferrin*1.42) * 100) is not reliable for Ferritin values above 1200 µg/L: in this case, those values were not included in final analysis. Statistical analysis was performed using the software IBM SPSS 22.0. Data are reported as mean with standard deviation (std. dev.), median with interquartile range (IQR), number and percentage, depending on underlying distribution. Student's t-test, Mann-Whitney, Kruskal–Wallis, Spearman correlation and χ² tests were used for statistical analysis.

**Results**

Table 1 summarises anthropometric features and characteristics of our sample. The intubation rate is particularly elevated because in our Hospital are present sub-intensive care units and because ICU stay lower than 48 hours (only for strict monitoring purposes) was an exclusion criteria. It is therefore likely the analysis accounts for a population of severely affected patients. CT scan patterns of low (L) or high (H) elastance refers to the phenotypes proposed by Gattinoni et al. [20]. Due to the exiguity of our sample and the different focus of our work, we intentionally did not test p-values for the clinical features reported in Table 1.
Table 1 Demographic and general sample description

| Reported cases | Male (%) | Female (%) |
|----------------|----------|------------|
| Gender (M/F)   | 25 (81)  | 6 (19)     |

| Variables | Male: median (IQR) | Female (median (IQR) |
|-----------|--------------------|----------------------|
| Age (year)| 62 (57 - 67)       | 71 (62 - 74)         |
| BMI (kg/m²)| 27.8 (25.3 - 31.1) | 29.4 (29.3 - 30.8)   |
| Symptoms-to-ICU (days) | 9 (8 - 12) | 7 (7 - 7) |
| In-hospital pre-ICU LOS (days) | 2 (1 - 5) | 2.5 (2 - 3) |
| ICU LOS    | 14 (9 - 19)        | 12.5 (11.2 - 16.7)   |
| PFmed      | 195 (159.5 - 220)  | 165.5 (136.1 - 183.3) |
| PLR        | 436 (218 - 623)    | 305 (180 - 565)      |
| CT scan (L:H) | 6:15 | 2:2 |
| Intubated patients (%) | 22 of 25 (88) | 6 of 6 (100) |
| Tracheostomy (%) | 21 of 25 (84) | 4 of 6 (67) |
| VAPs (%) | 13 of 25 (52) | 2 of 6 (33) |
| Pro-coagulative disorders (%) | 3 of 25 (12) | 0 of 6 (0) |
| Pnx (%) | 7 of 25 (28) | 1 of 6 (17) |
| CRRT (%) | 10 of 25 (40) | 1 of 6 (17) |
| Admitted from other centres (%) | 12 of 25 (48) | 3 of 6 (50) |
| Mortality (%) | 7 of 21 (33) | 1 of 6 (17) |

4 men still admitted in our ICU

BMI = body-mass index; CRRT = continuous renal-replacement therapy; CT scan = computed tomography (only those with both images and radiologic report available - H stay for High-elastance pattern and L stays for Low-elastance pattern); ICU = intensive care unit; IQR = interquartile range; LOS = length-of-stay; Mortality: 21 men over 25 enrolled because 4 are still in our ICU; PFmed = mean PaO₂/FiO₂ ratio during the first 24 hours of ICU stay; PLR = platelet-to-lymphocyte ratio on the day of ICU admission; Pnx = pneumothorax; Pro-coagulative disorders: deep-vein thrombosis, ischaemic stroke or massive pulmonary embolism; VAP = ventilator-acquired pneumonia.

A significant increase of TfSat levels (%) occurs between the first 48 hours of ICU stay and day 3 to 6 (Mann-Whitney, p-value = 0.026 - Figure 1). No other significant trends and modifications of iron parameters and lymphocyte subpopulations were found during ICU stay. Lymphocytes and their subpopulations do not show significant trends of modification either. [shortened]

Trends and modifications of iron parameters are reported in Figure 1, while trends and modifications of lymphocytes count and lymphocytic subgroups are reported in Figure 2.

Looking to secondary outcomes, neither iron parameters nor lymphocyte count correlate with mortality, PFmed or PLR. Their values are reported in Table 2.

Table 2a Iron parameters over time

|                | Day 1-2  | Day 3-6  | Day 7-10 | Day 11-14 | Day 15-18 |
|----------------|----------|----------|----------|-----------|-----------|
| Ferritin (µg/L)| 1236.5 (1648) | 1185 (1018) | 964.5 (1251) | 1470 (1866) | 755 (172) |
| Serum iron (µg/L) | 25.5 (69) | 73 (56) | 58 (61) | 55 (63) | 45 (8) |
| Transferrin (g/L) | 1.67 (0.73) | 1.82 (0.38) | 1.56 (0.58) | 1.88 (0.93) | 2.06 (0.15) |
| Transferrin Saturation (%) | 9 (7) | 33 (26.5) | 29 (26.5) | 22 (22) | 16 (1) |
| Transferrin Receptor (mg/L) | 1.14 (0.40) | 1.07 (0.49) | 0.99 (0.47) | 0.98 (0.58) | 1.00 (0.11) |

Page 4/10
Table 2b Lymphocyte subgroups over time

|          | Day 1-7  | Day 8-14 |
|----------|----------|----------|
| NK (10^9/L) | 44 (14.25) | 57.5 (50.5) |
|           | 17       | 16       |
| T - CD3 (10^9/L) | 286 (284.75) | 409.5 (422.5) |
|           | 17       | 16       |
| T - CD4 (10^9/L) | 246 (161) | 331 (364) |
|           | 16       | 17       |
| T - CD8 (10^9/L) | 86.5 (121) | 117.5 (117) |
|           | 18       | 16       |
| B         | 116 (146) | 102 (161) |
|           | 15       | 17       |

Table 2c Total lymphocyte count over time

|        | D1          | D2          | D3          | D4          | D5          | D6          | D7          | D8          | D9          | D10         | D11         | D12         | D13         | D14         |
|--------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|
| Lympho (10^9/L) | 0.630 (0.780) | 0.555 (0.450) | 0.610 (0.605) | 0.600 (0.493) | 0.670 (0.540) | 0.645 (0.330) | 0.655 (0.480) | 0.680 (0.550) | 0.840 (0.493) | 0.830 (0.750) | 0.780 (0.715) | 0.850 (0.650) | 0.860 (0.510) | 0.800 (0.340) |
|        | 14          | 18          | 20          | 21          | 22          | 22          | 22          | 22          | 19          | 21          | 21          | 18          | 17          | 15          |

Data are all expressed as median, interquartile range between brackets and number of measured cases in the second line.

The already described survival predictors in general hospital population (LDH, troponin, CRP and D-dimer) are not significantly associated with outcome, PLR or PFmed in our ICU population and do not show significant trends. Data are reported in Table 3.

D-dimer shows a non-significant tendency to increase after ICU admission (Kruskal-Wallis, p-value = 0.108, Figure 3). IL6 elevation is lower than reported by other studies on critically ill Covid-19 patients [21]. We found a debile correlation between IL6 levels and lymphocyte count on the day of ICU admission (8 cases, Spearman rho 0.714, p-value = 0.047), but the analysis is limited by the low amount of cases.

Table 3 Clinical biomarkers over time

|        | Day 1-2 | Day 3-6 | Day 7-10 | Day 11-14 | Day 15-18 |
|--------|---------|---------|----------|-----------|-----------|
| D-dimer (µg/L) | 1319 (1285) | 6820 (6619) | 3718 (4631) | 2959 (2923) | 2391 (2693) |
|         | 11      | 19      | 14       | 12        | 10        |
| LDH (U/L) | 476 (226) | 451 (205) | 425 (218) | 404 (134) | 376 (223) |
|         | 13      | 26      | 22       | 19        | 9         |
| CRP (mg/L) | 116 (46) | 192 (72) | 52 (190) | 129 (129) | 111 (117) |
|         | 13      | 21      | 16       | 17        | 10        |
| Troponin T (ng/L) | 19 (15) | 21 (10) | 18 (10) | 15 (18) | 18 (12) |
|         | 7       | 19      | 15       | 13        | 7         |
| IL6 (pg/mL) | 42.5 (47.4) | 9       | 7        | 7         | 7         |

Discussion

Cytokines release hyper-expresses Hepcidin, leading to Ferroportin internalisation and reduced iron absorption and availability in body fluids [22,23]. Serum iron and TfSat are known to decrease early after infections, inhibiting iron availability to the pathogen, but then return to almost-normal values within 7-10
Serum iron does not show significant modifications, but it follows the same trend of TfSat being part of the formula to calculate it. They both remain lower than the normal reference values during the whole infection. It is difficult to hypothesize the reason of their trend without proper laboratory research: the dramatic low levels at ICU admission might be expected, but the following increase during an acute phase of inflammatory response seems counter-intuitive. The described patients arrived in our ICU after a median of 7 to 9 days from symptoms onset: the physiologic progressive restoration of normal TfSat after 1 week of infection and the dysregulated cytokine response might contribute to TfSat elevation. Also, it has been described that acute respiratory distress syndrome (ARDS) causes reduced serum iron levels [27]: intubated Covid-19 patients suffer of this syndrome, while protective ventilation might theoretically restore normal iron levels. Ferritin is a very early and non-specific indicator of inflammation. It resulted to be the first severely elevated biomarker together with lymphopenia [1]: thus, its early dosage in at-home symptomatic patients might be extremely useful in individuating those who can benefit of early hospital admission. After its initial rise, ferritin can take longer than a month to normalise after an infection [24]. Thus, it remains elevated during ICU stay of Covid-19 patients. Despite being apparently futile, its dosage constitutes the key element to suspect secondary hemophagocytic lymphohistiocytosis (sHLH). sHLH is a frequently misdiagnosed syndrome related to viral infections and thus of primary importance in this Covid-19 pandemic. Overall, despite unable of a more detailed description, we demonstrate how iron metabolism is deranged in severe forms of Covid-19.

Lymphocytes are constantly reduced in ICU Covid-19 patients with respect to reference values [28]. All the subsets are also dramatically reduced, more than reported by other recent publications referring to non-ICU populations [9,29]. We observe a conserved CD4/CD8 ratio. The nadir of lymphopenia is on day 2 of ICU stay; a progressive tendency towards normalisation is more evident in patients experiencing positive outcome and ICU discharge. Similar timing of lymphocyte modifications was observed during Severe Acute Respiratory Disease (SARS) outbreak, despite with less dramatic reduction [30,31]. Being referred to critically ill patients, this more severe reduction of all lymphocyte subgroups might be an indicator of severity. To date, no other publications are available about ICU populations on lymphocytes subgroups.

Being such a specific subset of critically ill patients, many significant differences were not observable between survivors and non. These data might be relevant to researchers for a better understanding of the altered immunologic response in severely affected patients and to ICU clinicians. The study is affected by some limitations [the “limitations” section has been shortened to become more fluid, although no significant differences are present in its meaning]. The sanitary emergency and the previously unknown characteristics of this disease led to many difficulties. During the initial phase, it has been difficult to create an effective protocol shared between the operators and some data have been missed. We have frequently acted as a backup hospital to relieve other overloaded ICUs nearby: this means that, for a part of the reported cases, the first few days of ICU-stay occurred in a different unit and the dosage of relevant markers was missed during that initial phase. Being a monocentric study conceived during an emergency phase, the sample size is limited and cannot be increased: this led to the impossibility to detect and describe some more subtle physiologic processes. Finally, slightly different therapeutic approaches have been applied to patients following ongoing findings and different complications (ventilator-acquired pneumonia, pro-coagulative states, renal and hepatic insufficiency) have affected patients’ evolution: it is not possible to quantify how these differences affected iron metabolism and lymphocyte count.

Conclusions

We describe iron metabolism, lymphocyte subgroups count and other biomarkers in critically ill Covid-19 patients. This might be relevant for clinicians dealing with critical patients and provide further hints about the pathophysiology of this disease.

Iron metabolism has been repeatedly proposed as a potential therapeutic target during infections [32,33]. Pharmacologic advances have made available safer iron chelators [34]. This testifies the relevance of the topics investigated and how they might contribute to the development of novel therapeutic strategies against Covid-19.

Abbreviations

APP: acute phase-proteins; CRP: C-reactive protein; CRRT: continuous renal replacement therapy; ECMO: extracorporeal membrane oxygenation; HLH: hemophagocytic lymphohistiocytosis; IL-6: interleukin 6; IQR: interquartile range; LDH: lactate dehydrogenase; LOS: length-of-stay; MOF: multiple organ failure; PCR: polymerase chain reaction; PFmed: mean PaO\textsubscript{2}/FiO\textsubscript{2} ratio during the first 24 hours of ICU admission; PLR: platelet-to-lymphocyte ratio on the day of ICU admission; PPE: personal protective equipment; SARS: severe acute respiratory syndrome; SARS-CoV-2: SARS Coronavirus type 2; TfSat: Transferrin Saturation (%); VAP: ventilator-acquired pneumonia; WHO: World Health Organization.

Declarations

Ethics approval and consent to participate: protocol IR-COV, version 21\textsuperscript{st} of April 2020, accepted by Romagna Ethical Committee, under final revision.

Consent for publication: all clinical data are completely anonymised, discharged patients are being telephonically contacted to get informed consent.

Availability of data and materials: The datasets used and analysed during the current study are available from the corresponding author on reasonable request.

Competing interests: The authors declare that they have no competing interests.
Funding: none.

Authors' contribution: BG conceived the study project, wrote the paper and collected scientific literature; RE critically reviewed the study design, performed statistical analysis and contributed to drafting; GE, CA, MMCC, BE, VL and BL contributed to data collection, database curation and drafting; PV and AV supervised the project and critically reviewed the draft.

Acknowledgments: Authors thank the ICU colleagues for their contribution in respecting the investigation protocol in such a difficult time; we also thank Prof. Drakesmith (University of Oxford) for the vicinity and the disinterested support and incitation in continuing our data collection and Prof. Antonio Lucariello (Università degli Studi di Napoli, Federico II) for his contribution to the understanding of iron metabolism.

References

1. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;6736:1–9.
2. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020; Available from: https://doi.org/10.1007/s00134-020-05991-x
3. Pietrangelo A. Pathogens, Metabolic Adaptation, and Human Diseases - An Iron-Thrifty Genetic Model. Gastroenterology. 2015;149:834.
4. Cassat JE, Skaar EP. Iron in infection and immunity. Cell Host Microbe. 2013;13:509–19.
5. Drakesmith H, Prentice A. Viral infection and iron metabolism. Nat Rev Microbiol. 2008;6:541–52.
6. Drakesmith H, Prentice AM. Hepcidin and the Iron-Infection Axis. Science. 2012;338:768–72.
7. Litton E, Lim J. Iron Metabolism: An Emerging Therapeutic Target in Critical Illness. Crit Care. Critical Care; 2019;23:1–8.
8. Ganz T. Anemia of inflammation. N. Engl. J. Med. 1991;381:1148–57.
9. Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China Chuan. Clin Infect Dis. 2020; Available from: https://doi.org/10.1093/cid/ciaa248
10. Huang I, Panatara R. Lymphopenia in severe coronavirus disease-2019 (COVID-19): Systematic review and meta-analysis. J. Intensive Care. 2020; Available from: https://doi.org/10.1186/s40560-020-00453-4.
11. Velavan TP, Meyer CG. Mild versus severe COVID-19: Laboratory markers. Int. J. Infect. Dis. 2020;95:304–7.
12. Wang W, Chen S, Liu J-Jun, Kao C, Chen H, Chiang B, et al. Temporal Relationship of Viral Load, Ribavirin, Interleukin (IL)–6, IL-8, and Clinical Progression in Patients with Severe Acute Respiratory Syndrome. Clin Infect Dis. 2004;39:1071–5.
13. Cossarizza A, De Biasi S, Guaraldi G, Girardis M, Mussini C, Modena Covid-19 Working Group (MoCo19). SARS-CoV-2, the Virus that Causes COVID-19: Cytometry and the New Challenge for Global Health. Cytometry A. 2020;97:340-343.
14. Liu R, Wang Y, Li J, Han H, Xia Z, Liu F, et al. Decreased T cell populations contribute to the increased severity of COVID-19. Clin Chim Acta. 2020;508:110-114.
15. Wan S, Yi Q, Fan S, Lv J, Zhang X, Guo L, et al. Relationships among lymphocyte subsets, cytokines, and the pulmonary inflammation index in coronavirus (COVID-19) infected patients. Br J Haematol. 2020;189;428-437.
16. Wang F, Nie J, Wang H, Zhao Q, Xiong Y, Deng L, et al. Characteristics of Peripheral Lymphocyte Subset Alteration in COVID-19 Pneumonia. J Infect Dis. 2020;221:1762–9.
17. Aziz M, Fatima R, Assaly R. Elevated Interleukin-6 and Severe COVID-19: A Meta-Analysis. J Med Virol. 2020; Available from: https://doi.org/10.1002/jmv.25948
18. Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, Fan E, et al. Acute respiratory distress syndrome: The Berlin definition. JAMA. 2012;307:2526–33.
19. Qu R, Ling Y, Zhang Y, Wei L, Chen X, Li X, et al. Platelet-to-lymphocyte ratio is associated with prognosis in patients with Corona Virus Disease-19. J Med Virol. 2020; Available from: https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.25767
20. Gattinoni L, Chiurlo L, Chiarioni P Usana M, Romitti F, Brazzi L, et al. COVID-19 pneumonia: different respiratory treatment for different phenotypes? Intensive Care Med. 2020; Available from: https://doi.org/10.1007/s00134-020-06033-2.
21. Tu W-J, Cao J, Yu L, Hu X, Liu Q. Clinico-laboratory study of 25 fatal cases of COVID-19 in Wuhan. Intensive Care Med. 2020; Available from: https://doi.org/10.1007/s00134-020-06023-4
22. Netem E, Tuttle MS, Powelson J, Vaughn MD, Donovon A, Ward DMV, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science. 2004;306:2090–3.
23. Sabelli M, Montos G, Caleffi C, Caleffi A, Oliveto S, Biffin S, et al. Human macrophage ferroportin biology and the basis for the ferroportin disease. Hepatology. 2017;65:1512–25.
24. Edeas M, Saleh J, Peyssonnaux C. Iron: Innocent bystander or vicious culprit in COVID-19 pathogenesis? Int J Infect Dis. Int J Infect Dis; 2020; Available from: https://doi.org/10.1016/j.ijid.2020.05.110
27. Stites SW, Nelson ME, Wesselius LJ. Transferrin concentrations in serum and lower respiratory tract fluid of mechanically ventilated patients with COPD or ARDS. Chest. 1995;107:1681–5.

28. Bisset LR, Lung TL, Kaelin M, Ludwig E, Dubs RW. Reference values for peripheral blood lymphocyte phenotypes applicable to the healthy adult population in Switzerland. Eur J Haematol. 2004;72:203–12.

29. Chen J, Subbarao K. The Immunobiology of SARS. Annu Rev Immunol. 2007;25:443–72.

30. He Z, Zhao C, Dong Q, Zhuang H, Song S, Peng G, et al. Effects of severe acute respiratory syndrome (SARS) coronavirus infection on peripheral blood lymphocytes and their subsets. Int J Infect Dis. 2005;9:323–30.

31. Wong RSM, Wu A, To KF, Lee N, Lam CWK, Wong CK, et al. Haematological manifestations in patients with severe acute respiratory syndrome: Retrospective analysis. Br Med J. 2003;326:1358–62.

32. Dalamaga M, Karampela I, Mantzoros CS. Commentary: Could iron chelators prove to be useful as an adjunct to COVID-19 Treatment Regimens? Metabolism. 2020, https://doi.org/10.1016/j.metabol.2020.154260.

33. Liu W, Zhang S, Nekhai S, Liu S. Depriving Iron Supply to the Virus Represents a Promising Adjuvant Therapeutic Against Viral Survival. Curr. Clin. Microbiol. 2020. Available from: https://doi.org/10.1007/s40588-020-00140-w

34. Bernhardt P V. Coordination chemistry and biology of chelators for the treatment of iron overload disorders. Dalt. Trans. 2007;30:3214–20. [13 references less]

Figures

**Figure 1**

Iron parameters Legend figure 1: distribution over time of the tested iron parameters with their units of measure. Box plots indicate median with interquartile range, dots indicate outliers. Groups specify the timing by which the dosage was effectuated form the moment of ICU admission, round brackets in the lower line indicate the number of patients tested for each group. In figure 1E, * indicates significant difference (p-value > 0.05).
Figure 2

lymphocytes count Legend figure 2: distribution over time of lymphocytes and their tested subgroups, with their units of measure. Box plots indicate median with interquartile range, dots indicate outliers. Groups specify the timing by which the dosage was effectuated form the moment of ICU admission. The number of patients tested is reported in table 2b and 2c. Lymphocytes subsets merges all the subgroups to make their trend over time more readable.
D-dimer levels Legend figure 3: D-dimer levels over time from the moment of ICU admission. It is observable a non-significant trend toward increase after the first 48h. It might be relevant to explain the increased tendency to hypercoagulability of Covid-19 patients. Box plots indicate median with interquartile range, dots indicate outliers. Groups specify the timing by which the dosage was effectuated form the moment of ICU admission.